Last week, I caught up with a friend I hadn’t seen in a while. After we chatted a bit about the challenges of the past year, she suddenly asked, “Isn’t it strange that they haven’t found a cure for ALS yet? I wonder what’s holding them back?” My mind…
Search results for:
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. More than one-quarter of amyotrophic lateral sclerosis (ALS) patients — with or without a family history of ALS — have…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Amyotrophic lateral sclerosis (ALS) patients with a short disease duration and fast progression showed better responses to Orion’s investigational oral…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treatment is complete in 20 patients enrolled in the randomized ROPALS clinical trial assessing the safety, tolerability and early…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Researchers have found a unique immune molecular signature that can distinguish amyotrophic lateral sclerosis (ALS) patients with rapidly progressing disease…
Actimed Therapeutics is developing S-oxprenolol to prevent muscle wasting and body mass loss due to amyotrophic lateral sclerosis (ALS), using proceeds from a recent license agreement with Faraday Pharmaceuticals. Under the agreement, Faraday acquired global rights to develop and commercialize S-oxprenolol for muscle-affecting disorders other than ALS, particularly…
The ALS Association is now accepting applications for the Jane Calmes ALS Scholarship Fund, aimed at supporting U.S. students whose lives are affected financially as well as personally by amyotrophic lateral sclerosis (ALS). Going on its third year, the fund helps to cover costs for young people wanting…
Note: This story was updated on April 16, 2021, to note that Scribe’s founding year was 2018, not 2017. Scribe Therapeutics has raised $100 million in funding to develop CRISPR-based gene editing tools and advance its pipeline of therapies for neurodegenerative diseases, such as…
People at risk or suspected of having some of the most common neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), may now access a genetic test at no charge that could diagnose the condition, and open the way to treatment. Launched by Invitae,…
I think a lot about how a parent’s ALS affects kids. Recently, an online friend lost her husband to ALS. She has small children and has been posting about their grief and the tender questions her kids have asked. It’s difficult enough for an adult to process the pain of…